Revance completed the acquisition of HintMD for $190m.

Revance Therapeutics, a biotechnology company, completed the acquisition of HintMD, a payment processing company, for $190m. “The acquisition of HintMD augments Revance’s strong aesthetics product offering, enabling us to transform both the practice and patient experience with an innovative fintech platform. This transaction leverages our existing and planned commercial infrastructure and, we believe along with our suite of facial injectables, grows our U.S. aesthetics market opportunity to more than $2.6," Mark Foley, Revance President and CEO.